Immunization of macaques with single-cycle simian immunodeficiency virus (SIV) stimulates diverse virus-specific immune responses and reduces viral loads after challenge with SIVmac239

David T. Evans, Jennifer E. Bricker, Hannah B. Sanford, Sabine Lang, Angela Carville, Barbra A. Richardson, Michael Piatak, Jeffrey D. Lifson, Keith G. Mansfield, Ronald Charles Desrosiers

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Genetically engineered simian immunodeficiency viruses (SIV) that is limited to a single cycle of infection was evaluated as a nonreplicating AIDS vaccine approach for rhesus macaques. Four Mamu-A*01+ macaques were inoculated intravenously with three concentrated doses of single-cycle SIV (scSIV). Each dose consisted of a mixture of approximately equivalent amounts of scSIV strains expressing the SIVmac239 and SIVmac316 envelope glycoproteins with mutations in nef that prevent major histocompatibility complex (MHC) class I downregulation. Viral loads in plasma peaked between 104 and 105 RNA copies/ml on day 4 after the first inoculation and then steadily declined to undetectable levels over the next 4 weeks. SIV Gag-specific T-cell responses were detected in peripheral blood by MHC class I tetramer staining (peak, 0.07 to 0.2% CD8+ T cells at week 2) and gamma Interferon (IFN-γ) enzyme-linked immunospot (ELISPOT) assays (peak, 50 to 250 spot forming cells/106 peripheral blood mononuclear cell at week 3). Following the second and third inoculations at weeks 8 and 33, respectively, viral loads in plasma peaked between 10 2 and 104 RNA copies/ml on day 2 and were cleared over a 1-week period. T-cell-proliferative responses and antibodies to SIV were also observed after the second inoculation. Six weeks after the third dose, each animal was challenged intravenously with SIVmac239. All four animals became infected. However, three of the four scSIV-immunized animals exhibited 1 to 3 log reductions in acute-phase plasma viral loads relative to two Mamu-A*01+ control animals. Additionally, two of these animals were able to contain their viral loads below 2,000 RNA copies/ml as late as 35 weeks into the chronic phase of infection. Given the extraordinary difficulty in protecting against SIVmac239, these results are encouraging and support further evaluation of lentiviruses that are limited to a single cycle of infection as a preclinical AIDS vaccine approach.

Original languageEnglish (US)
Pages (from-to)7707-7720
Number of pages14
JournalJournal of Virology
Volume79
Issue number12
DOIs
StatePublished - Jun 2005
Externally publishedYes

Fingerprint

Simian immunodeficiency virus
Simian Immunodeficiency Virus
Macaca
viral load
Viral Load
Immunization
immunization
immune response
Viruses
viruses
AIDS Vaccines
T-lymphocytes
vaccination
major histocompatibility complex
RNA
animals
Major Histocompatibility Complex
T-Lymphocytes
dosage
Infection

ASJC Scopus subject areas

  • Immunology

Cite this

Immunization of macaques with single-cycle simian immunodeficiency virus (SIV) stimulates diverse virus-specific immune responses and reduces viral loads after challenge with SIVmac239. / Evans, David T.; Bricker, Jennifer E.; Sanford, Hannah B.; Lang, Sabine; Carville, Angela; Richardson, Barbra A.; Piatak, Michael; Lifson, Jeffrey D.; Mansfield, Keith G.; Desrosiers, Ronald Charles.

In: Journal of Virology, Vol. 79, No. 12, 06.2005, p. 7707-7720.

Research output: Contribution to journalArticle

Evans, David T. ; Bricker, Jennifer E. ; Sanford, Hannah B. ; Lang, Sabine ; Carville, Angela ; Richardson, Barbra A. ; Piatak, Michael ; Lifson, Jeffrey D. ; Mansfield, Keith G. ; Desrosiers, Ronald Charles. / Immunization of macaques with single-cycle simian immunodeficiency virus (SIV) stimulates diverse virus-specific immune responses and reduces viral loads after challenge with SIVmac239. In: Journal of Virology. 2005 ; Vol. 79, No. 12. pp. 7707-7720.
@article{8238d7a5577b469187d7b446e69e9117,
title = "Immunization of macaques with single-cycle simian immunodeficiency virus (SIV) stimulates diverse virus-specific immune responses and reduces viral loads after challenge with SIVmac239",
abstract = "Genetically engineered simian immunodeficiency viruses (SIV) that is limited to a single cycle of infection was evaluated as a nonreplicating AIDS vaccine approach for rhesus macaques. Four Mamu-A*01+ macaques were inoculated intravenously with three concentrated doses of single-cycle SIV (scSIV). Each dose consisted of a mixture of approximately equivalent amounts of scSIV strains expressing the SIVmac239 and SIVmac316 envelope glycoproteins with mutations in nef that prevent major histocompatibility complex (MHC) class I downregulation. Viral loads in plasma peaked between 104 and 105 RNA copies/ml on day 4 after the first inoculation and then steadily declined to undetectable levels over the next 4 weeks. SIV Gag-specific T-cell responses were detected in peripheral blood by MHC class I tetramer staining (peak, 0.07 to 0.2{\%} CD8+ T cells at week 2) and gamma Interferon (IFN-γ) enzyme-linked immunospot (ELISPOT) assays (peak, 50 to 250 spot forming cells/106 peripheral blood mononuclear cell at week 3). Following the second and third inoculations at weeks 8 and 33, respectively, viral loads in plasma peaked between 10 2 and 104 RNA copies/ml on day 2 and were cleared over a 1-week period. T-cell-proliferative responses and antibodies to SIV were also observed after the second inoculation. Six weeks after the third dose, each animal was challenged intravenously with SIVmac239. All four animals became infected. However, three of the four scSIV-immunized animals exhibited 1 to 3 log reductions in acute-phase plasma viral loads relative to two Mamu-A*01+ control animals. Additionally, two of these animals were able to contain their viral loads below 2,000 RNA copies/ml as late as 35 weeks into the chronic phase of infection. Given the extraordinary difficulty in protecting against SIVmac239, these results are encouraging and support further evaluation of lentiviruses that are limited to a single cycle of infection as a preclinical AIDS vaccine approach.",
author = "Evans, {David T.} and Bricker, {Jennifer E.} and Sanford, {Hannah B.} and Sabine Lang and Angela Carville and Richardson, {Barbra A.} and Michael Piatak and Lifson, {Jeffrey D.} and Mansfield, {Keith G.} and Desrosiers, {Ronald Charles}",
year = "2005",
month = "6",
doi = "10.1128/JVI.79.12.7707-7720.2005",
language = "English (US)",
volume = "79",
pages = "7707--7720",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "12",

}

TY - JOUR

T1 - Immunization of macaques with single-cycle simian immunodeficiency virus (SIV) stimulates diverse virus-specific immune responses and reduces viral loads after challenge with SIVmac239

AU - Evans, David T.

AU - Bricker, Jennifer E.

AU - Sanford, Hannah B.

AU - Lang, Sabine

AU - Carville, Angela

AU - Richardson, Barbra A.

AU - Piatak, Michael

AU - Lifson, Jeffrey D.

AU - Mansfield, Keith G.

AU - Desrosiers, Ronald Charles

PY - 2005/6

Y1 - 2005/6

N2 - Genetically engineered simian immunodeficiency viruses (SIV) that is limited to a single cycle of infection was evaluated as a nonreplicating AIDS vaccine approach for rhesus macaques. Four Mamu-A*01+ macaques were inoculated intravenously with three concentrated doses of single-cycle SIV (scSIV). Each dose consisted of a mixture of approximately equivalent amounts of scSIV strains expressing the SIVmac239 and SIVmac316 envelope glycoproteins with mutations in nef that prevent major histocompatibility complex (MHC) class I downregulation. Viral loads in plasma peaked between 104 and 105 RNA copies/ml on day 4 after the first inoculation and then steadily declined to undetectable levels over the next 4 weeks. SIV Gag-specific T-cell responses were detected in peripheral blood by MHC class I tetramer staining (peak, 0.07 to 0.2% CD8+ T cells at week 2) and gamma Interferon (IFN-γ) enzyme-linked immunospot (ELISPOT) assays (peak, 50 to 250 spot forming cells/106 peripheral blood mononuclear cell at week 3). Following the second and third inoculations at weeks 8 and 33, respectively, viral loads in plasma peaked between 10 2 and 104 RNA copies/ml on day 2 and were cleared over a 1-week period. T-cell-proliferative responses and antibodies to SIV were also observed after the second inoculation. Six weeks after the third dose, each animal was challenged intravenously with SIVmac239. All four animals became infected. However, three of the four scSIV-immunized animals exhibited 1 to 3 log reductions in acute-phase plasma viral loads relative to two Mamu-A*01+ control animals. Additionally, two of these animals were able to contain their viral loads below 2,000 RNA copies/ml as late as 35 weeks into the chronic phase of infection. Given the extraordinary difficulty in protecting against SIVmac239, these results are encouraging and support further evaluation of lentiviruses that are limited to a single cycle of infection as a preclinical AIDS vaccine approach.

AB - Genetically engineered simian immunodeficiency viruses (SIV) that is limited to a single cycle of infection was evaluated as a nonreplicating AIDS vaccine approach for rhesus macaques. Four Mamu-A*01+ macaques were inoculated intravenously with three concentrated doses of single-cycle SIV (scSIV). Each dose consisted of a mixture of approximately equivalent amounts of scSIV strains expressing the SIVmac239 and SIVmac316 envelope glycoproteins with mutations in nef that prevent major histocompatibility complex (MHC) class I downregulation. Viral loads in plasma peaked between 104 and 105 RNA copies/ml on day 4 after the first inoculation and then steadily declined to undetectable levels over the next 4 weeks. SIV Gag-specific T-cell responses were detected in peripheral blood by MHC class I tetramer staining (peak, 0.07 to 0.2% CD8+ T cells at week 2) and gamma Interferon (IFN-γ) enzyme-linked immunospot (ELISPOT) assays (peak, 50 to 250 spot forming cells/106 peripheral blood mononuclear cell at week 3). Following the second and third inoculations at weeks 8 and 33, respectively, viral loads in plasma peaked between 10 2 and 104 RNA copies/ml on day 2 and were cleared over a 1-week period. T-cell-proliferative responses and antibodies to SIV were also observed after the second inoculation. Six weeks after the third dose, each animal was challenged intravenously with SIVmac239. All four animals became infected. However, three of the four scSIV-immunized animals exhibited 1 to 3 log reductions in acute-phase plasma viral loads relative to two Mamu-A*01+ control animals. Additionally, two of these animals were able to contain their viral loads below 2,000 RNA copies/ml as late as 35 weeks into the chronic phase of infection. Given the extraordinary difficulty in protecting against SIVmac239, these results are encouraging and support further evaluation of lentiviruses that are limited to a single cycle of infection as a preclinical AIDS vaccine approach.

UR - http://www.scopus.com/inward/record.url?scp=19944424151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944424151&partnerID=8YFLogxK

U2 - 10.1128/JVI.79.12.7707-7720.2005

DO - 10.1128/JVI.79.12.7707-7720.2005

M3 - Article

C2 - 15919923

AN - SCOPUS:19944424151

VL - 79

SP - 7707

EP - 7720

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 12

ER -